文献速递肿瘤 PET/CT

镓-68标记成纤维细胞活化蛋白抑制剂PET在胃肠道肿瘤中的诊断与管理价值

Gallium-68-labeled fibroblast activation protein inhibitor PET in gastrointestinal cancer: insights into diagnosis and management.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-06-03

本研究前瞻性入组后回顾性分析120例胃肠道恶性肿瘤患者的121次68Ga-FAPI PET检查,比较其与常规影像和18F-FDG PET的诊断效能及治疗指导价值。68Ga-FAPI PET诊断准确率95.0%,显著高于常规影像的65.1%和18F-FDG PET的69.0%(均p<0.001),治疗符合率96.7%亦显著更高,并改变了22.9%和23.8%患者的治疗决策。

要点

  • 68Ga-FAPI PET诊断准确率95.0%,高于常规影像65.1%和18F-FDG PET 69.0%(均p<0.001)。
  • 68Ga-FAPI PET使30.3%和26.2%患者诊断较常规影像和18F-FDG PET发生修正。
  • 68Ga-FAPI PET治疗符合率96.7%,高于常规影像75.2%和18F-FDG PET 76.2%(均p<0.001)。

核心结论

  • 68Ga-FAPI PET在胃肠道肿瘤中表现出显著的诊断效能,可实现更准确的分期并指导及时的治疗修正,从而对临床管理产生关键影响。

研究设计与样本

  • 患者最初前瞻性入组一项评估68Ga-FAPI PET诊断价值的临床试验,本研究对2020年6月至2021年5月间120例胃肠道恶性肿瘤患者的121次68Ga-FAPI PET检查进行回顾性分析。
  • 评估未治疗患者的初始分期和治疗后患者的再分期,根据NCCN指南确定影像所推动的治疗方案,最终诊断和治疗参照标准由专门的多学科团队确定。
  • 将68Ga-FAPI PET的诊断效能和治疗指导与常规影像(CI)及18F-FDG PET进行比较。

主要发现

  • 68Ga-FAPI PET诊断准确率为95.0%,显著高于常规影像的65.1%和18F-FDG PET的69.0%(均p<0.001)。
  • 与常规影像和18F-FDG PET相比,68Ga-FAPI PET分别在30.3%和26.2%的患者中修正了诊断。
  • 68Ga-FAPI PET指导治疗与参照标准的一致率为96.7%,显著高于常规影像的75.2%和18F-FDG PET的76.2%(均p<0.001)。
  • 与常规影像和18F-FDG PET相比,68Ga-FAPI PET分别在22.9%和23.8%的患者中改变了治疗。

关键数值与推荐

  • 68Ga-FAPI PET诊断准确率95.0%,常规影像65.1%,18F-FDG PET 69.0%(均p<0.001)。
  • 68Ga-FAPI PET治疗符合率96.7%,常规影像75.2%,18F-FDG PET 76.2%(均p<0.001)。
  • 68Ga-FAPI PET对比常规影像修正诊断率30.3%、改变治疗率22.9%;对比18F-FDG PET修正诊断率26.2%、改变治疗率23.8%。

临床怎么用

  • 原文结论指出68Ga-FAPI PET在胃肠道肿瘤中诊断效能显著,可实现更准确分期并指导及时的治疗修正,对临床管理有重要影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Gallium-68-labeled fibroblast activation protein inhibitor (68Ga-FAPI) is an emerging promising tumor tracer. This study aims to evaluate the diagnostic efficiency of 68Ga-FAPI PET in gastrointestinal cancer, and to determine its potential impact on clinical management. METHODS: Patients with malignancies were prospectively enrolled in a clinical trial to evaluate the diagnostic value of 68Ga-FAPI PET. One hundred twenty patients with gastrointestinal malignancies (121 68Ga-FAPI PET scans) between June 2020 and May 2021 were retrospectively analyzed. Initial staging of untreated patients and restaging of treated patients were evaluated. The treatment scheme promoted by imaging was determined according to NCCN guidelines. Final diagnosis and treatment reference standards were determined by a dedicated multidisciplinary team. The diagnostic performance and treatment guidance of 68Ga-FAPI PET were compared with those of conventional imaging (CI) and 18F-FDG PET. RESULTS: The diagnostic accuracy of 68Ga-FAPI PET was much higher than that of CI and 18F-FDG PET (95.0% vs. 65.1% and 69.0%, respectively, both p < 0.001). 68Ga-FAPI PET revised diagnosis in 30.3% and 26.2% of patients compared with CI and 18F-FDG PET. The accordance rate of 68Ga-FAPI PET-guided treatment in comparison with the reference standard was significantly higher than that of CI and 18F-FDG PET (96.7% vs. 75.2% and 76.2%, respectively, both p < 0.001). 68Ga-FAPI PET changed treatment in 22.9% and 23.8% of patients compared with CI and 18F-FDG PET. CONCLUSIONS: 68Ga-FAPI PET showed remarkable diagnostic performance in gastrointestinal cancer, resulting in more accurate staging and guidance for timely treatment revision, thereby having a critical impact on clinical management. TRIAL REGISTRATION: NCT04554719. Registered September 8, 2020-retrospectively registered, http://clinicaltrails.gov/show/NCT04554719.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Qin C, Song Y, Gai Y, et al. Gallium-68-labeled fibroblast activation protein inhibitor PET in gastrointestinal cancer: insights into diagnosis and management. Eur J Nucl Med Mol Imaging. 2022. PMID: 35657428. doi:10.1007/s00259-022-05847-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。